These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11471124)

  • 1. Securing viral safety for plasma derivatives.
    Morgenthaler JJ
    Transfus Med Rev; 2001 Jul; 15(3):224-33. PubMed ID: 11471124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk of infection from plasma products: specific preventative strategies.
    Burnouf T; Radosevich M
    Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific inactivation of viruses which can potentially contaminate blood products.
    Horowitz B
    Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral infectivity of albumin and plasma protein fraction.
    Erstad BL
    Pharmacotherapy; 1996; 16(6):996-1001. PubMed ID: 8947970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety issues for plasma derivatives and benefit from NAT testing.
    Willkommen H; Schmidt I; Löwer J
    Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies in assuring blood safety: An overview.
    Epstein JS
    Biologicals; 2010 Jan; 38(1):31-5. PubMed ID: 20110174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma for fractionation: safety and quality issues.
    Farrugia A
    Haemophilia; 2004 Jul; 10(4):334-40. PubMed ID: 15230946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
    Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Viral safety concept: application to blood and blood products].
    Trouvin JH
    Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance of prions during plasma protein manufacture.
    Burdick MD; Pifat DY; Petteway SR; Cai K
    Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems].
    Burnouf T; Goubran HA; Radosevich M; El-Ekiaby M
    Transfus Clin Biol; 2008 Jun; 15(3):129-34. PubMed ID: 18538608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of needs for plasma for fractionation in Europe.
    Burckhardt JJ
    Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. West Nile virus and blood product safety in Germany.
    Pfleiderer C; Blümel J; Schmidt M; Roth WK; Houfar MK; Eckert J; Chudy M; Menichetti E; Lechner S; Nübling CM
    J Med Virol; 2008 Mar; 80(3):557-63. PubMed ID: 18205233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old and new tests: where will it end?
    Holland PV
    Vox Sang; 2000; 78 Suppl 2():67-70. PubMed ID: 10938931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.